Hemochromatosis Screening

Introduction to Screening Recommendations

The American College of Physicians and the U.S. Preventive Services Task Force conclude that there is insufficient evidence to recommend for or against universal population screening for hereditary hemochromatosis 1, 2, 3, 4

The American College of Physicians recommends against routine screening of the general asymptomatic population due to insufficient evidence on the balance between benefits and risks 1, 2, 3, 4
Only 10% of individuals homozygous for C282Y develop clinically significant organ damage 5
If screening is decided upon in asymptomatic populations, the group with the highest yield is non-Hispanic white men, using serum ferritin and transferrin saturation on a single occasion 1, 2

First-degree relatives of patients with hemochromatosis should be strongly recommended for screening 1, 2, 6, 7
The risk of developing the disease is significantly higher than in the general population 1, 2
Patients with suggestive clinical manifestations such as diabetes type 2, cardiac arrhythmias, cardiomyopathies, liver insufficiency, hepatomegaly, cirrhosis, elevated liver enzymes, hepatocellular carcinoma, arthritis, hypogonadism, or skin pigmentation changes should undergo active case-finding 1, 2

Serum ferritin and transferrin saturation should be performed simultaneously as initial tests 6, 7
Transferrin saturation ≥45% is the diagnostic threshold with the highest sensitivity 6, 7
Ferritin levels >200 µg/L in women or >300 µg/L in men indicate elevation 1, 2, 6, 7

If transferrin saturation >45% and/or ferritin is elevated, proceed with HFE gene mutation analysis (C282Y and H63D) 6, 7
This strategy is more cost-effective than universal initial genetic screening 6

When ferritin >1,000 µg/L with elevated liver enzymes, consider liver biopsy to evaluate cirrhosis in C282Y homozygotes with ferritin >1,000 µg/L, elevated liver enzymes, hepatomegaly, or age >40 years 6, 7
Ferritin >1,000 µg/L with ALT/AST elevation and platelets <200 predicts cirrhosis in approximately 80% of C282Y homozygotes 6

Perform ECG and echocardiography in patients with severe iron overload to evaluate arrhythmias and cardiac dysfunction 7
Cardiac MRI in patients with signs of cardiac disease or juvenile forms of hemochromatosis 6, 7
Liver MRI to quantify hepatic iron concentrations in cases with unclear cause of hyperferritinemia 6, 7

The penetrance of clinical disease among individuals with C282Y mutation is low: 50% do not demonstrate elevated transferrin saturation and 99% are free of clinical symptoms 5
Most C282Y homozygotes identified at any time do not manifest clinically significant disease 3, 4

Psychological burden of being labeled with a chronic disease 3, 4
Potential consequences on ability to obtain health or life insurance 3, 4
Concerns associated with genetic testing without qualified genetic counseling 1, 2, 3, 4

Discuss with the patient before performing genetic tests: available treatment and its efficacy, costs involved, impact of disease labeling, insurability, and psychological well-being 1, 2
Possibility of yet unknown genotypes associated with hemochromatosis 1, 2

Elevated ferritin with normal transferrin saturation is an unusual pattern for classic HFE-related hemochromatosis, which typically presents with elevated transferrin saturation (>45%) as the earliest and most sensitive marker 6
However, some non-classic forms of hemochromatosis may present with this pattern, so genetic testing is still indicated 6

When hemochromatosis is confirmed, perform screening of all adult first-degree relatives with genetic tests for C282Y after appropriate counseling 6, 7
Combine genetic tests with phenotype (ferritin and transferrin saturation) in relatives 6